Summary of findings 2. Summary of findings.

Population: Adult female participants with PCOS Intervention: Atorvastatin Comparison: Placebo
Outcomes	Number of participants (RCTs)	Mean difference of atorvastatin compared to placebo (95% CI)	The certainty of evidence (GRADE)
Total testosterone	125 (4)	‐0.27 nmol/L (‐0.50 to ‐0.04)	Very low 1, 2,3
FAI	65 (2)	‐2.59 (‐3.62 to ‐1.57)	Very low 1, 2, 3
SHBG	65 (2)	3.11 nmol/L (0.23 to 5.99)	Low 1, 3
Androstenedione	125 (4)	‐1.37 nmol/L (‐2.26 to ‐0.49)	Very low 1, 2, 3
DHEAS	125 (4)	‐0.63 μmol/L (‐1.12 to ‐0.15)	Low 1, 3
Acronyms and grades
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; DHEAS: dehydroepiandrosterone sulphate; FAI: free androgen index; RCT: randomized controlled trial; SHBG: sex hormone binding globin
GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 High risk of bias in source of funding and sponsorship bias in more than one study.

2 Significant heterogeneity.

3 Small sample size.